19 Декабря 2018
According to Goldstein Research, India pharmaceutical market size is anticipated to cross USD 76.7 billion by 2024, growing at a CAGR of 15.9% over the forecast period 2016-2024. More deals are expected to happen in Indian companies acquiring assets in US/Europe, rather than MNCs acquiring Indian companies. India Pharmaceutical Market segmentation has been done on the basis of type and geography. India has become the third largest global generic API merchant market by 2016, with a 7.2 percent market share and the India pharmaceutical industry accounts for the second largest number of Abbreviated New Drug Applications (ANDAs). India pharmaceutical market, by players, the highest expenditure based on research and development is done by Sun Pharma (USD 352 Million), followed by Dr. Reddy (USD 199 million). Further, Cipla formed an exclusive partnership with Serum Institute of India to sell vaccines in South Africa.

Market Segmentation
On the basis of our in-depth analysis, India Pharmaceutical Market can be segmented as follows:
By Type
•    Active Pharmaceutical Ingredients (APIs)
•    Branded
•    Generics
•    Contract Research and Manufacturing Services
•    Formulations (CRAMS)
•    Chronic
•    Cardiovascular
•    Anti-Diabetes
•    Gastro-Intestinal
•    Neurological
•    Acute
•    Anti-infectives
•    Respiratory
•    Pain
•    Gynecology
•    Biosimilars

“India Pharmaceutical Market Outlook 2024” contains a detailed overview of the India pharmaceutical market. On the basis of our in-depth analysis, the market can be segmented in terms of market segmentation by type & geography.

Further, for the in-depth analysis, India Pharmaceutical Market Report encompasses the industry growth drivers, market challenges, risk analysis, market attractiveness, BPS (Base Point Scale) analysis, Porter’s five force model and SWOT analysis. This market report also includes competitive outlook of some of the major players profiling of companies such as Sun Pharma, Dr. Reddy, Lupin, Cipla, Aurobindo, Candela. Glenmark, Torrent Pharma, Alkem Lab, Divis Lab, Piramal Enter, Ipca Lab, Glaxo SmithKline, Abbott India, Biocon, Jubilant life, Sanofi India, Wockhardt, Pfizer, DrLal Path Lab, Merck, Hikal, Novartis India, Eris Life, etc. The company profiles include business strategy, geographical revenue distribution, major information of the companies which encompasses business outlook, products, services and industries catered, financial analysis of the company and recent developments. Overall, the report represents the India pharmaceutical market trends along with market forecast that will help industry consultants, technology providers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market-centric strategies according to the ongoing and expected trends in the future.
Steve Blade
Goldstein Research
Goldstein Research